Increasing Time Costs and Copayments for Prescription Drugs: An Analysis of Policy Changes in a Complex Environment: Increasing Time Costs and Copayments for Prescription Drugs by Domino, Marisa Elena et al.
RESEARCH ARTICLE
Increasing Time Costs and Copayments
for Prescription Drugs: An Analysis
of Policy Changes in a
Complex Environment
Marisa Elena Domino, Bradley C. Martin, Elizabeth Wiley-Exley,
Shirley Richards, Abel Henson, Timothy S. Carey, and Betsy Sleath
Objective. To estimate the effect of two separate policy changes in the North Carolina
Medicaid program: (1) reduced prescription lengths from 100 to 34 days’ supply, and
(2) increased copayments for brand name medications.
Data Sources/Study Setting. Medicaid claims data were obtained from the Centers
for Medicare and Medicaid Services for January 1, 2000–December 31, 2002.
Study Design. We used a pre–post controlled partial difference-in-difference-in-
differences design to examine the effect of the policy change on adults in North Car-
olina; adult Medicaid recipients from Georgia served as controls. Outcomes examined
include medication adherence and Medicaid expenditures.
Data Collection/Extraction Methods. Data were aggregated to the person-quarter
level. Individuals in HMOs, nursing homes, pregnant, or deceased in the quarter were
excluded.
Principal Findings. Both policies decreased medication adherence. The days’ supply
policy had a much larger effect on adherence than did the copayment increase. Total
Medicaid spending declined from the days’ supply policy, but the copayment policy
resulted in a net increase in Medicaid expenditures.
Conclusions. Although Medicaid costs decreased with the change in days supply
policy, these savings were due to reduced adherence to these chronic medications.
Additional research should examine the effect of these policy changes from the per-
spective of Medicaid enrollees.
Key Words. Medicaid, prescription drugs, chronic medications, days’ supply
Over the past 20 years major advances in the pharmacological treatment of
hypertension, diabetes, schizophrenia, and depression have led to improved
outcomes in these and other chronic conditions (Gray et al. 2000; Pignone,
Phillips, and Mulrow 2000; Chobanian et al. 2003; Conley et al. 2003; Sokol




et al. 2005; Lee, Grace, and Taylor 2006; Rasmussen, Chong, and Alter 2007),
yet the cost of these treatments is high (Weideman et al. 2002; Kennedy,
Coyne, and Sclar 2004; Sokol et al. 2005; Centers for Disease Control and
Prevention 2009). The growth of pharmaceutical spending in many of these
chronic disease categories is particularly high in state Medicaid programs
(Banthin and Miller 2006).
The reasons for increasing pharmaceutical costs to Medicaid are man-
ifold, and attempts to constrain them are common. Multiple strategies have
been used by both public and private insurers, including prior authorization,
formulary restrictions, tiered formularies with increased copayments for more
expensive/nonpreferred medications, mail-order pharmacies, and restrictions
of the number of days’ supply (Soumerai et al. 1991; Berglin et al. 2003;
Soumerai 2004; Ridley and Axelsen 2006; Chernew et al. 2008).
Cost-containment strategies have proven to be effective in altering pat-
terns of care but often spill over to the use of other types of health services,
including medication adherence and discontinuation, and hospital and nurs-
ing home use, especially in low-income populations or among those with
chronic illnesses (Soumerai et al. 1987; Huskamp et al. 2003; Domino et al.
2004a; Hsu et al. 2006; Ridley and Axelsen 2006; Chernew and Newhouse
2008). Individuals with limited benefits often have unfavorable clinical out-
comes and lower adherence rates for hypertension, hyperlipidemia, and di-
abetes medications (Hsu et al. 2006). Yet the evidence about whether these
strategies are net cost-saving, or even cost-effective, is scarce (Soumerai 2004).
One restriction that many insurers use is to allow subscribers to fill only a
month’s supply of medications, even those that are used chronically. Cur-
rently, 41 out of 46 states for which information on days’ supply restrictions
were available restrict the days’ supply in their Medicaid programs to 34 days
or fewer.1 Such a strategy may be cost saving if patients undergo frequent
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medication changes mid-prescription resulting in the discard of unused por-
tions (Domino et al. 2004b). However, once a patient has been established and
the dose is titrated for chronic medications, drug doses generally remain stable
(Basile 2003; Neuser et al. 2005; Mago 2008) and adherence to consistent
dosing is an important part of therapy.
Despite the wide use of limited days’ supply policies, little research has
examined the use of these policies on pharmaceutical use and costs, and no
literature yet contrasts the use of restricted days’ supply policies over other de-
mand-side efforts such as increased cost sharing. This paper examines a natural
experiment in the North Carolina (NC) Medicaid program in which the allowed
days’ supply per prescription was decreased from 100 days to 34 days on July 1,
2001, followed by an increase in copayment for brand name drugs on October 1,
2001. We used similar individuals on Georgia Medicaid as a comparison group
and examined both medication adherence and total Medicaid expenditures.
CONCEPTUAL MODEL
Both out-of-pocket and time costs affect demand for prescription medications.
A decrease in the allowed days’ supply is an increase in time costs because
medication users have to take more frequent trips to the pharmacy. There is
also a potential increase in out-of-pocket costs when a copayment is required
monthly instead of every 3 months. There is unobserved heterogeneity in the
benefits of being compliant to medication and in individuals’ costs of traveling
to the pharmacy, across medication classes and across individuals within
medication classes that will affect medication use.
We hypothesized that the increase in both types of cost to the patient of
obtaining a prescription will not only decrease adherence, but that decreased
adherence will affect the use of other health care services. The direction of the
effect of decreasing prescription lengths on other measures of health care use,
such as outpatient medical visits, is not obvious a priori. If other services, such
as outpatient visits, emergency room (ER) visits, or hospital stays, serve as
substitutes for prescription medication use, than an increase in the cost of
obtaining a prescription should increase the use of these other services due to
declines in health status. The magnitude of the effect from copayment changes
may not be the same as the magnitude for changes in time costs.
However, there are at least three situations where decreased adherence
could decrease the use of other health care expenditures. First, if greater drug
costs disproportionately deter inappropriate medication use that may lead to
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iatrogenic harms, then health expenditures could be reduced (Chernew and
Newhouse 2008). Secondly, shorter prescription lengths combined with a
fixed number of prescription refills may be desirable if they are linked to
greater office visits and greater opportunities to monitor side effects or physical
status and improve health. Finally, reduced prescription lengths could in-
crease interactions with pharmacists and thus increase opportunities for mon-
itoring side effects or adjusting dosage, which could lead to reductions in other
health care use. We modeled the reduced form effect on total Medicaid ex-
penditures (pharmacy and other health services). The sign of the effect is
ambiguous a priori, depending on whether the savings from lower pharma-
ceutical use outweigh any increases in health care spending.
METHODS
We used a pre–post controlled partial difference-in-difference-in-differences
(DDD) design to examine the effect of the policy changes on adults in NC; adult
Medicaid recipients from Georgia (GA) were used as a comparison group. The
maximum days’ supply changed in NC on July 1, 2001 from 100 to 34 days and
the copayment for brand name prescriptions increased from U.S.$1 to U.S.$3 on
October 1, 2001. GA is an appropriate control group for NC because the max-
imum days’ supply limitation of 31 days did not change during our study period
and both states have a similar population size (8.6 M), poverty rate (13 versus 14
percent), and percent of the population reporting African American race (29
versus 22 percent) and Hispanic ethnicity (6 versus 5 percent). GA, however, did
have an increase in its copayment for nonpreferred prescriptions from U.S.$0.50
to between U.S.$0.50 and U.S.$3.00 for nonpreferred medications on July 1,
2001. While this policy change in our control state during the study period is not
necessarily desirable, we believe it had minimal impact on our comparison for
several reasons. First, the vast majority (79–94 percent) of chronic medications
were in the ‘‘preferred’’ categories before the policy change and thus did not
experience an increase in copayments. Second, a number of Medicaid eligibles
were excluded from the copayment increase (e.g., under age 21, pregnant
women, those in institutions, or under hospice care). Finally, our methodology
accounts for this difference between GA and NC in the policy period.
Data
Claims data for this analysis were obtained from the Centers for Medicare and
Medicaid Services for both states and cover the study period from January 1,
2000–December 31, 2002, yielding 18-month pre- and postpolicy periods.
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Sample
We separately examined individuals in the NC and GA Medicaid programs
who use medications for chronic conditions in the following six categories: (1)
anti-hypertensives, (2) anti-diabetic medications (sulfonylureas and met-
formin), (3) lipid-lowering drugs (Gemfibrozil and HMG-CoA reductase in-
hibitors [statins]), (4) seizure-disorder medications, (5) antidepressants, and (6)
antipsychotics. Conditions and medications were selected based on their rel-
atively high prevalence in the Medicaid population; generally stable dosing
once therapeutic effect has been achieved; and the potential for observable
effects of nonadherence to medications on health services use. Diagnoses were
required for associated conditions in all classes except statins and antidiabetic
medications because of the potential for off-label use. The range of hypoth-
esized effects on health services is listed in Table 1.
Inclusion Criteria
Individuals age 19–64 enrolled in the Medicaid program who received at least
90 days’ supply of target medications, not necessarily continuously, over the
18-month prepolicy period were included in each of the six samples. All
included individuals were required to be fully eligible for Medicaid benefits,
thus ruling out Medicare partial dual enrollees who only received Medicare
cost-sharing assistance from Medicaid (often called ‘‘SLMB/QMBs’’).
Data on total Medicaid expenditures and expenditures by service type
(outpatient, inpatient, ER, and pharmacy) were aggregated to the quarterly
level for each individual enrollee. Quarterly data were only included if the
individual was enrolled in Medicaid for at least 90 percent of the quarter.
Table 1: Included Drug Classes and Hypothesized Effects of Nonadherence













Seizure-disorder medications High Yes
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Quarters were excluded if the enrollee was enrolled in an HMO, in a nursing
home, was pregnant, or died. We removed one quarter (third quarter of 2002)
of data in GA from all drug variables due to a suspiciously low level of pre-
scriptions in one month in the raw claims files. All remaining quarters on
Medicaid were included, whether or not spending occurred.
We ran sensitivity analyses on individuals who received at least 438
medication days ( 5 80 percent of the 18 month pre-period) and otherwise met
other inclusion and exclusion criteria. We also ran models on individuals who
were continuously enrolled, defined as having at least 11 quarters of Medicaid
enrollment out of 12 possible, but results were virtually identical to those
reported here, due to the large percent (62 percent or greater) of the sample
population that was continuously enrolled.
Measures
Adherence was measured using the proportion of days covered (PDC) measure
(Benner et al. 2002; Peterson et al. 2007), which expresses the fraction of the
days in the quarter for which at least one medication in the target class was
received. Actual medication-taking behavior among those with dispensed pre-
scriptions is not available in our data. The PDC is preferred to the Medication
Possession Ratio (MPR) for adherence to a class of medications since the MPR
can overstate adherence if multiple products in the same category are filled
(Martin et al. 2009). The PDC instead calculates daily indicators of medication
use and divides by the number of days in the quarter, and therefore it cannot be
41.0. We also created an indicator of quarters in which the PDC is 480
percent, an often-used threshold for adherence (Keene et al. 2005; Andrade et
al. 2006; Karve et al. 2009). We removed the first quarter of 2000 from the PDC
analyses due to left censoring but retained its drug expenditures.
Expenditures are examined from the state Medicaid program’s per-
spective. We examine expenditures on target medications and total Medicaid
expenditures, which includes expenditures on services, pharmaceuticals, and
other items recorded in the Medicaid claims files. Expenditures on prescrip-
tion drugs are before rebates from manufacturers. Because a linear time trend
was used, no adjustments were made for inflation.
Analytic Methods
We examined the influence of the policy changes on measures of Medicaid
spending and adherence using partial DDD ordinary least squares regression
models with individual fixed effects. The person-level fixed effects will control
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for any time-invariant differences between patients and prescribers in each
state, as well as in the subpopulations described below. Although the time
trends in outcomes were similar in the prepolicy period between states, we
allowed for separate linear time trends for NC and GA and used state-specific
seasonal dummy variables to adjust for seasonal effects.
The partial DDD approach uses not only a comparison state (GA) but
also separates out enrollees who were more likely to be affected by the policy
changes. We identified individuals in NC who received a prescription in the
prepolicy period of longer than 40 days; we anticipated that the effect of the
days’ supply policy would be concentrated in this group. A similar group is not
available in GA due to the restriction of 31 days during the full study period;
thus, we refer to this as a partial DDD.
We examined the ways in which individuals with long prescriptions
(LPs) differ from other individuals in each drug class cohort through logit
analysis. Results varied across the six disease categories (not reported; avail-
able from authors by request) but generally showed that women, the contin-
uously enrolled, disabled, older, and more comorbid individuals were more
likely to receive longer prescriptions, while minorities and those with greater
hospital use during the study period were less likely to fill an LP. The use of
person-specific fixed effects controls for time-invariant differences and be-
tween LPs and others in NC. Of remaining concern is whether the time trends
in measures of use were different between LPs and others in NC before the
prescription drug policies were implemented. For four of the six cohorts, we
found no evidence of different trends in the rate of service access or expen-
ditures for those who accessed services between LPs and others in NC before
the policy change. Small differences in trends in service access and expen-
ditures were detected in the remaining two samples (antidepressants and an-
tipsychotics, respectively). This means that for these two samples, our
estimated postperiod effects might overstate the actual effect due to the policy
change, and thus we urge caution in interpreting results from these cohorts.
State policy making occurs in a complex environment and the days’
supply change studied here is no exception. On October 1, 2001, 3 months
after the days’ supply change, NC raised the copayment amount for brand
name prescription drugs from U.S.$1 to U.S.$3, leaving the generic medica-
tion copayment at U.S.$1. This copayment change should not have affected
those using only generic medications, but it may have affected patterns of care
for those using brand name medications. We split medication users into those
who used only generic medications (3.0–18.4 percent; Table 3) and those who
used brand name medications. Along these two dimensions (LP/not LP;
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generic/brand users), we can identify individuals who were most likely
affected by the two policy changes (Table 2).
We focus on three separate policy periods and their potential effects in
NC: (1) the pre-policy period, January 1, 2000–June 30, 2001, with an allowed
longer prescription length and U.S.$1 copayments for both generic and brand-
name medications; (2) the transition period, July 1, 2001–September 30, 2001,
when the allowed days’ supply was shortened; and (3) the postperiod, October
1, 2001–December 31, 2002, where the shortened days’ supply policy contin-
ued, compounded by the greater copayment for brand name prescriptions.
Empirically, we allowed for a separate effect during the transition period
and the postpolicy period. Interactions between the NC indicator, the LP and
generic/brand name indicators and the transition and postperiods were the
key variables of interest and are reported in the tables. Because of the non-
trivial number of quarters without Medicaid expenditures, we used two-part
OLS regression models (Duan 1983; Duan et al. 1983), modeling the prob-
ability of use in the quarter separately, using a linear probability mode to
accommodate the fixed effects, from the level of expenditures among obser-
vations with nonzero spending. Robust standard errors are reported.
RESULTS
Each of the medication cohorts had 8,300–62,000 unique nonelderly adults per
state, with up to 12 observations each, yielding sample sizes for each of the six
medication cohorts from 212,000 to almost one million observations (Table 3).
All samples were predominately female with varying racial and ethnic
Table 2: North Carolina Populations Affected by Policy Changes





Transition; SP No No
Transition; LP Yes No
Post; generic only, SP No No
Post; generic only, LP Yes No
Post; brand name user, SP No Yes
Post; brand name user, LP Yes Yes
LP, individuals who received a long prescription ( 40 days) in the prepolicy period; Post, the
subsequent quarters; SP, those who only received short prescriptions; Transition, the first quarter
after the days’ supply policy change.
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compositions. Partly because of the inclusion criteria that required at least 90
days of filled medications, most of the sample was continuously enrolled in
Medicaid during the full study period (62–80 percent). Individuals in the sample
had a high number of comorbidies, averaging between 3.9 and 7.0 diagnostic
groups other than the qualifying condition. Between 22 and 37 percent of
individuals in NC received prescriptions of 440 days in the prepolicy period.
Mean adherence, measured by the PDC, was fairly consistent across
classes, ranging from 0.73 for antidepressants to 0.83 for seizure disorders. The
majority of all quarters with target medication use demonstrated an adherence
level of 0.80 PDC or greater, and this figure ranged from 51 percent for
antidepressants to 70 percent of quarters for seizure disorder medications.
Individuals had average quarterly spending on target medications ranging
from U.S.$120 for hypertension medications in GA to U.S.$710 for antipsy-
chotic medications in NC. Total Medicaid expenditures ranged from
U.S.$2,015 to U.S.$2,815 per quarter. Per capita expenditures on most ser-
vices were higher in NC than GA, but the trends in spending were very similar
during the prepolicy period.
DDD models (Table 4) consistently found a significant decrease in med-
ication adherence after the policy changes in all six medication classes. During
the transition period, in which only the days supply change was effective, ad-
herence decreased by 1.5–4.6 percentage points across disease categories
among individuals with a prior LP. During the postperiod, in which individuals
were potentially also affected by the change in brand name copayment, we see a
range of effects. The LPs who received generic medications only and thus should
be affected only by the days’ supply policy had an estimated 2.9–8.0 percentage
point decrease in adherence in four of the medication classes; no significant
effect on adherence was found among seizure or antipsychotic medication users.
Among those who did not receive an LP but used brand name medications and
thus were potentially affected by the copayment policy but not the days’ supply
policy, we find a much smaller decline in adherence, of 0.4–1.8 percentage
points in four of the classes, a small increase in adherence among those with a
seizure disorder (0.67 percentage point), and the effect on antipsychotic users
was not statistically significant. Finally, among those hypothesized to be affected
by both policies, the range of the effect was an estimated decline in adherence
from 2.1 to 5.7 percentage points. For all classes except statins, this effect was at
least as large as the estimated effect of the days’ supply only (on LPs with generic
use only), indicating compound effects of the two policies.
Adherence decreases substantially reduced the percent of quarters in
which individuals were at least 80 percent adherent to target medications.
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Decreases were observed in all six categories for at least some of the affected
categories and ranged from 2.6 to 13.2 percentage point reductions, indicating
that both policies increased the rate at which chronic medication users were
not adherent to their prescribed medication. The estimated declines were
again larger for those affected by the days’ supply policy than the increase in
copays and were larger still for those affected by both policies.
The NC days’ supply policy change was associated with a decrease of 1.7–
5.5 percentage points in the probability of filling a target medication in four
classes during the transition quarter (all except seizure disorder and antipsy-
chotic medications) followed by an increase of 3.0–5.5 percentage points in the
probability of filling a target prescription each quarter during the postperiod by
generic-only LPs, probably because prescription lengths no longer spanned an
entire quarter. We cannot reject the hypothesis of no effect of the days’ supply
policy during the postperiod in two of the six categories (diabetes and statins).
Surprisingly, we find an increase in the probability of filling medications from
the copayment policy in all six classes, ranging from 2.4 to 11.0 percentage
points. This could be due to medication switches that might bring individuals to
the pharmacy more often. Finally, among those affected by both polices, we
again find a substantially greater probability of filling a prescription for a target
medication, ranging from 2.6 to 12.7 percentage points higher.
Medicaid expenditures for those with a target prescription decrease
substantially among those affected by the days’ supply policy. This effect
ranged from U.S.$76 to U.S.$257 during the transition period for LPs to
U.S.$19 to U.S.$66 during the postperiod. In contrast, we find increases
in spending among target medication users affected only by the copayment
policy in five of the six classes, ranging from U.S.$6/quarter to U.S.$162/
quarter. Finally, among those affected by both policies, we again see overall
declines in target medication expenditures, ranging from U.S.$29 to
U.S.$115 per quarter across all six classes.
We examined whether the policy changes in NC were associated with
spillovers to other types of services, such as outpatient care, inpatient use, or
ER visits and found little evidence of spillovers across all medication classes
(results not reported; available upon request).
Overall, total Medicaid spending on all services declined during the
transition period in all six classes, ranging from U.S.$245 to U.S.$440
per person per quarter for service users. Because of high levels of service use
each quarter, we find little effect of the days’ supply policy on the probability of
using Medicaid funded services each quarter. During the postperiod, how-
ever, we find almost no effect of the days’ supply policy alone in most
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medication categories. Among those exposed only to the copayment increase,
we find mixed results across medication classes. The probability of using
services increased in four of the six categories (all except statins and seizure
medications), while the level of spending among service users increased for
only two categories (antipsychotics and antihypertensives). Among those ex-
posed to both policies, however, we again find small increases in the prob-
ability of accessing Medicaid services in only two categories (antidepressants
and antipsychotics) but decreases in expenditures for five of the six categories
(only statins showed no change). Since very little spillover effects on services
were found, the fact that the magnitude of the change in total Medicaid ex-
penditures was greater than the change in expenditures on target medication
may point to changes in the utilization of other medications outside the classes
examined here, which would also be exposed to the policy changes.
DISCUSSION
The decrease in allowed days’ supply and the increase in the brand name
copayment in the North Carolina Medicaid program substantially decreased
adherence across individuals using a broad range of medications for chronic
conditions. The observed decreases from the days’ supply policy were larger
than those from the copayment policy, indicating that the increase in the time
costs from more frequent trips to the pharmacy were more of a barrier to
medication adherence than the increased copayment. The effects of the policy
changes were weaker in the two medication classes in which decreased ad-
herence is thought to have a more immediate and severe impact on health
(seizure disorder and antipsychotic medications). The decreases in adherence
occurred at a mean level of usage generally thought to show clinical effects.
The probability of being 80 percent adherent decreased between 1 and 13
percentage points, implying that the policy changes resulted in a substantial
decrease in medication adherence for chronic medication users in NC.
The cost savings associated with the policy change were substantial. We
estimate a reduction in total spending on the order of 10–18 percent per LP
during the transition period, and a steady state decrease in spending of be-
tween 1.3 and 8.0 percent during the full postperiod from the days’ supply
policy alone. The copayment increase, however, was associated with total cost
increases in five of the six medication classes, ranging from 0.4 to 8.0 percent;
a modest decrease in total expenditures was only observed among users
of diabetic medications. Among those subject to both policy changes, cost
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declines were again consistently observed across all medication classes and
ranged from 2.2 to 16.8 percent of mean expenditures.
The order of the two policy changes may have important implications.
Had the copayment increase been implemented before the days’ supply
change, its effect would be expected to be lessened from that estimated here, as
the additional charge for brand-name medications would be experienced less
frequently. The implementation of the copayment change during the shorter
days’ supply period increases the generalizability of these results, because the
vast majority of state Medicaid programs have shorter prescription lengths.
The fact that these lower levels of adherence did not seem to translate to
increases in the cost of other health services may have several explanations.
First, it is possible that the level of changes in adherence observed here may
not be sufficiently large to result in adverse health effects; our administrative
data do not contain clinical information such as blood pressures or measures of
diabetic control that might be more sensitive to adherence changes. Individ-
uals who do experience a clinical effect, such as a worsening of symptoms from
reduced medication use, may simply absorb these effects, using either infor-
mal care or treatments or possibly tolerating greater disease burden. Alter-
natively, the 18-month postperiod may not be long enough for decreased
medication adherence to spillover to the greater use of other services.
A number of limitations should be noted. Administrative measures of
adherence such as the PDC may not reflect actual medication adherence. These
measures may also not be sophisticated enough to pick up changes in recorded
adherence that may affect health care use. For example, PDC will equal 0.5 for
someone who takes the recommended dose for only half the days in the month
as well as for someone who takes half the recommended daily dose for all the
days in the month, although these two strategies may have substantially different
clinical outcomes. In addition, estimated effects of the separate policy changes
were identified through somewhat different subpopulations; as with all differ-
ence-in-difference analyses, if other policies disproportionately affected these
subpopulations during the post or transition periods, we are at risk of attributing
the effects to the policy changes studied herein.
This analysis focused only on costs to the Medicaid program and did not
factor in the additional costs such a policy change imposes on individuals
using medications through more frequent trips to the pharmacy. The cost of
these trips may be compounded when travel is difficult, such as in rural areas
or in populations such as the elderly or disabled.
Although we found evidence of Medicaid cost-savings in these six cat-
egories of chronic medication users as a result of the shorter prescription
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length, previous analyses (Domino et al. 2004b) found through a simulation
exercise that if compliance were unaffected, the reduced days’ supply would
actually increase medication expenditures. This was because more frequent
visits to the pharmacy substantially increased the pharmacy dispensing fees,
outweighing the estimated savings from the differed wastage of drug products.
Here, we found that adherence was affected and was critical to the cost
implications of this policy.
Beginning on October 1, 2003, NC Medicaid recipients were allowed to
obtain 90 days’ supply of generic, noncontrolled medications following a 30
days’ supply prescription for the same medication. This policy change may be
an efficient option that will likely both deter wastage from switching prescrip-
tions as well as maintain lower costs for both the program and Medicaid
recipients; the actual effects, of course, remain to be evaluated.
While increasing fiscal pressure faced by states to trim Medicaid ex-
penditures may have motivated the broad dissemination of shorter days’ sup-
ply and higher copayment policies, the associated decrease in adherence
should be followed closely. Lower rates of medication adherence among the
chronically ill may eventually reduce the savings to Medicaid budgets dem-
onstrated here, or possibly affect other outcomes, such as employment or even
mortality. Shortened days’ supply policies are not limited to Medicaid pro-
grams and the trade-off among shorter prescription lengths, short-run costs,
and adherence has implications for private payors and Medicare Part D pol-
icies as well.
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